PIK3CA and cancer: In spite of the crossover inhibition of other lipid and protein kinases (for example, LY294002 also inhibits mTOR, casein kinase 2 (CK2), DNA-dependent protein kinase (DNA-PK) and others) [164], and their unfavorable pharmaceutical properties, both wortmannin and LY294002 have served as important research tools for more than a decade in elucidating the role of PI3K in the biology of human cancer [165-170].